Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank93
5Y CAGR+20.7%
Studio
Year-over-Year Change

Year-over-year operating income growth rate

5Y CAGR
+20.7%/yr
Long-term compound
Percentile
P93
Near historical high
vs 5Y Ago
2.6x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202418.87%
2023-52.24%
2022-36.61%
2021-11.48%
2020-1.46%
20197.37%
201811.46%
2017-0.24%
2016-8.12%
2015-10.45%